Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML

Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell adhesion to the surrounding bone marrow stroma...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaitseva, Lyubov, Murray, Megan Y., Shafat, Manar S., Lawes, Matthew J., MacEwan, David J., Bowles, Kristian M., Rushworth, Stuart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259448/
https://www.ncbi.nlm.nih.gov/pubmed/25294819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259448/
https://www.ncbi.nlm.nih.gov/pubmed/25294819

Ejemplares similares